middle.news
Neurizon Advances ALS Drug NUZ-001 Despite $7.28M Half-Year Loss
2:28pm on Monday 17th of February, 2025 AEDT
•
Biotechnology
Read Story
Neurizon Advances ALS Drug NUZ-001 Despite $7.28M Half-Year Loss
2:28pm on Monday 17th of February, 2025 AEDT
Key Points
Losses surged 1770% to $7.28 million for H1 FY2025
NUZ-001 accepted into HEALEY ALS Platform Trial
Positive interim clinical results showing slowed ALS progression
EMA grants SME status and Orphan Medicinal Product Designation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE